ROBERT KRANCE to Lymphoproliferative Disorders
This is a "connection" page, showing publications ROBERT KRANCE has written about Lymphoproliferative Disorders.
Connection Strength
0.373
-
Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes. Transplantation. 2004 Sep 15; 78(5):755-7.
Score: 0.201
-
Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood. 2004 May 15; 103(10):3979-81.
Score: 0.048
-
Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood. 2015 Jun 25; 125(26):4103-13.
Score: 0.026
-
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995 Jan 07; 345(8941):9-13.
Score: 0.026
-
Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol. 1995 Jan; 89(1):98-103.
Score: 0.026
-
Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts. Hum Gene Ther. 1994 Mar; 5(3):381-97.
Score: 0.024
-
Correction of Duncan's syndrome by allogeneic bone marrow transplantation. Lancet. 1993 Sep 04; 342(8871):587-8.
Score: 0.023